Wells Fargo Maintains Alnylam at Equal-Weight, Cuts Target to $220
Wells Fargo maintained its Equal-Weight rating on Alnylam Pharmaceuticals and lowered its price target to $220 from $253.
Wells Fargo maintained its Equal-Weight rating on Alnylam Pharmaceuticals and lowered its price target to $220 from $253.